Effects of the factor xa inhibitor, fondaparinux, on the stability of atherosclerotic lesions in apolipoprotein e-deficient mice

Circulation Journal

Volumn 79, Issue 11, 2015, Pages 2499-2508

  Zuo, Pengfei ^a   Zhou, Qianxing ^a   Zuo, Zhi ^a   Wang, Xin ^a   Chen, Long ^a   Ma, Genshan ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Atherosclerosis; Fondaparinux; FXa inhibitor; Inflammation; Plaque stability

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; APOLIPOPROTEIN E; CD31 ANTIGEN; CELL SURFACE PROTEIN; CHOLESTEROL; COLLAGENASE 3; EARLY GROWTH RESPONSE FACTOR 1; FONDAPARINUX; GAMMA INTERFERON; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAC 2 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOKINE; MMP13 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; POLYSACCHARIDE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOLIPOPROTEIN E DEFICIENT MOUSE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LESION SIZE; MALE; MORPHOMETRICS; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; PLAQUE COMPOSITION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ATHEROSCLEROSIS; BLOOD; BLOOD CLOTTING; BRACHIOCEPHALIC TRUNK; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; GENETICS; KNOCKOUT MOUSE; METABOLISM; NECROSIS; PATHOLOGY; TIME FACTOR;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD COAGULATION; BRACHIOCEPHALIC TRUNK; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FIBROSIS; INFLAMMATION MEDIATORS; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MICE, KNOCKOUT; NECROSIS; PLAQUE, ATHEROSCLEROTIC; POLYSACCHARIDES; TIME FACTORS;

EID: 84944810903     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0285     Document Type: Article

References (55)

1. Fenning RS, Wilensky RL. New insights into the vulnerable plaque from imaging studies. Curr Atheroscler Rep 2014; 16: 397
2. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014; 114: 1852-1866
3. Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, et al. Evaluation of plaque stability of advanced atherosclerotic lesions in apoE-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 432080
4. Jobi K, Rauch BH, Dangwal S, Freidel K, Doller A, Eberhardt W, et al. Redox regulation of human protease-activated receptor-2 by activated factor X. Free Radic Biol Med 2011; 51: 1758-1764
5. Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 2008; 172: 309-320
6. Lange S, Gonzalez I, Pinto MP, Arce M, Valenzuela R, Aranda E, et al. Independent anti-angiogenic capacities of coagulation factors X and Xa. J Cell Physiol 2014; 229: 1673-1680
7. Rauch BH, Millette E, Kenagy RD, Daum G, Clowes AW. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ Res 2004; 94: 340-345
8. Napoli C, de Nigris F, Wallace JL, Hollenberg MD, Tajana G, De Rosa G, et al. Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions. J Clin Pathol 2004; 57: 513-516
9. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86: 1-36
10. Leizorovicz A, Becker F, Buchmüller A, Quéré I, Prandoni P, Decousus H. Clinical relevance of symptomatic superficial-vein thrombosis extension: Lessons from the CALISTO study. Blood 2013; 122: 1724-1729
11. Silvestri F, Pasca S, Labombarda A, Barbi A, Desideri M, Guidi P, et al. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: Results of a single-center, retrospective study. Minerva Med 2014; 105: 221-228
12. Ko RH, Michieli C, Lira JL, Young G. FondaKIDS II: Long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res 2014; 134: 643-647
13. Malz R, Weithauser A, Tschöpe C, Schultheiss HP, Rauch U. Inhibition of coagulation factor Xa improves myocardial function during CVB3-induced myocarditis. Cardiovasc Ther 2014; 32: 113-119
14. Frank RD, Schabbauer G, Holscher T, Sato Y, Tencati M, Pawlinski R, et al. The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation and neutrophil accumulation in kidney ischemia- reperfusion injury. J Thromb Haemost 2005; 3: 531-540
15. Iba T, Aihara K, Watanabe S, Yanagawa Y, Yamada A, Koichiro N, et al. Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome. Cardiovasc Ther 2013; 31: 280-284
16. Sumi A, Yamanaka-Hanada N, Bai F, Makino T, Mizukami H, Ono T. Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice. Biol Pharm Bull 2011; 34: 824-830
17. Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003; 102: 2731-2735
18. Puchtler H, Meloan SN. Demonstration of phosphates in calcium deposits: A modification of von Kossa’s reaction. Histochemistry 1978; 56: 177-185
19. Ma Y, Ma L, Guo Q, Zhang S. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients. J Exp Clin Cancer Res 2010; 29: 85
20. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA 2005; 293: 681-689
21. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
22. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402
23. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013; 112: 1973-1979
24. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19
25. Krantz MJ, Kaul S. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51). J Am Coll Cardiol 2013; 62: 777-781
26. Fishbein MC. The vulnerable and unstable atherosclerotic plaque. Cardiovasc Pathol 2010; 19: 6-11
27. Galis ZS. Vulnerable plaque: The devil is in the details. Circulation 2004; 110: 244-246
28. Ray BK, Shakya A, Turk JR, Apte SS, Ray A. Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque: Role of SAF-1 in the induction process. Circ Res 2004; 95: 1082-1090
29. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
30. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005; 102: 15575-15580
31. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-830
32. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance. Hum Pathol 1995; 26: 450-456
33. Da Pozzo E, Barsotti MC, Bendinelli S, Martelli A, Calderone V, Balbarini A, et al. Differential effects of fondaparinux and bemiparin on angiogenic and vasculogenesis-like processes. Thromb Res 2012; 130: e113-e122, doi:10.1016/j.thromres.2012.03.013
34. Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE Jr. Anticoagulation inhibits tumor cellmediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014; 123: 101-112
35. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27: 1456-1462
36. De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J 2014; 78: 1775-1781
37. Hezi-Yamit A, Wong PW, Bien-Ly N, Komuves LG, Prasad KS, Phillips DR, et al. Synergistic induction of tissue factor by coagulation factor Xa and TNF: Evidence for involvement of negative regulatory signaling cascades. Proc Natl Acad Sci USA 2005; 102: 12077-12082
38. Daubie V, Cauwenberghs S, Senden NH, Pochet R, Lindhout T, Buurman WA, et al. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta 2006; 1763: 860-869
39. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2–/– mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897
40. Iba T, Miyasho T. Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Crit Care 2008; 12: R86
41. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2292-2301
42. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207
43. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 2001; 21: 1662-1667
44. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-887
45. Girndt M, Kohler H. Interleukin-10 (IL-10): An update on its relevance for cardiovascular risk. Nephrol Dial Transplant 2003; 18: 1976-1979
46. Fukuda D, Aikawa M. Expanding role of delta-like 4 mediated notch signaling in cardiovascular and metabolic diseases. Circ J 2013; 77: 2462-2468
47. Nishihira K, Imamura T, Yamashita A, Hatakeyama K, Shibata Y, Nagatomo Y, et al. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. Eur Heart J 2006; 27: 1685-1689
48. Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: Relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-616
49. Lutgens E, van Suylen RJ, Faber BC, Gijbels MJ, Eurlings PM, Bijnens AP, et al. Atherosclerotic plaque rupture: Local or systemic process? Arterioscler Thromb Vasc Biol 2003; 23: 2123-2130
50. Ishikawa T, Hatakeyama K, Imamura T, Date H, Shibata Y, Hikichi Y, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003; 91: 287-292
51. Asadullah K, Sterry W, Volk HD. Interluekin-10 therapy: Review of a new approach. Pharmacol Rev 2003; 55: 241-269
52. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002; 169: 7019-7025
53. Uemura S. Invasive imaging of vulnerable atherosclerotic plaques in coronary artery disease. Circ J 2013; 77: 869-875
54. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550-2563
55. Xiong J, Zhu Z, Liu J, Wang Y, Li Z. Role of protease activated receptor-2 expression in renal interstitial fibrosis model in mice. J Huazhong Univ Sci Technolog Med Sci 2005; 25: 523-526.